http://api.archives-ouvertes.fr/search/?fq=halId_s:hal-03253026&fl=title_s,en_title_s,docid,label_s,en_label_s,authIdHal_s,halId_s,structId_i,uri_s,keyword_s,en_keyword_s,authLastNameFirstName_s,journalTitle_s,abstract_s,en_abstract_s,producedDate_tdate,producedDateY_i,language_s&sort=publicationDate_s+desc
authors
- Zheng Tuyu
- Ghasemi David
- Okonechnikov Konstantin
- Korshunov Andrey
- Sill Martin
- Maass Kendra
- Benites Goncalves da Silva Patricia
- Ryzhova Marina
- Gojo Johannes
- Stichel Damian
- Arabzade Amir
- Kupp Robert
- Benzel Julia
- Taya Shinichiro
- Adachi Toma
- Shiraishi Ryo
- Gerber Nicolas
- Sturm Dominik
- Ecker Jonas
- Sievers Philipp
- Selt Florian
- Chapman Rebecca
- Haberler Christine
- Figarella‑branger Dominique
- Reifenberger Guido
- Fleischhack Gudrun
- Rutkowski Stefan
- Donson Andrew
- Ramaswamy Vijay
- Capper David
- Ellison David
- Herold-Mende Christel
- Schuller Ulrich
- Brandner Sebastian
- Hernaiz Driever Pablo
- Kros Johan
- Snuderl Matija
- Milde Till
- Grundy Richard
- Hoshino Mikio
- Mack Stephen
- Gilbertson Richard
- Jones David T.W.
- Kool Marcel
- von Deimling Andreas
- Pfister Stefan
- Sahm Felix
- Kawauchi Daisuke
- Pajtler Kristian
keywords
- Ependymoma
- Supratentorial
- PLAGL1
- EWSR1
- FOXO1
- EP300
- Gene fusion
abstract
Molecular groups of supratentorial ependymomas comprise tumors with ZFTA-RELA or YAP1-involving fusions and fusion-negative subependymoma. However, occasionally supratentorial ependymomas cannot be readily assigned to any of these groups due to lack of detection of a typical fusion and/or ambiguous DNA methylation-based classification. An unbiased approach with a cohort of unprecedented size revealed distinct methylation clusters composed of tumors with ependymal but also various other histological features containing alternative translocations that shared ZFTA as a partner gene. Somatic overexpression of ZFTA-associated fusion genes in the developing cerebral cortex is capable of inducing tumor formation in vivo, and cross-species comparative analyses identified GLI2 as a key downstream regulator of tumorigenesis in all tumors. Targeting GLI2 with arsenic trioxide caused extended survival of tumor-bearing animals, indicating a potential therapeutic vulnerability in ZFTA fusion-positive tumors.
more information